Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 2/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5165444 | 1.00 | LMNA (0.37) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL536484 | 1.00 | LMNA (0.37) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL4082207 | 1.00 | LMNA (0.37) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL8155983 | 0.98 | LMNA (0.35) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL18486548 | 0.97 | LMNA (0.34) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL18486485 | 0.97 | LMNA (0.34) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL526988 | 0.95 | MPI (0.37) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| Phosphoric Acid SCHEMBL19583205 | 0.93 | MPI (0.36) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL321588 | 0.92 | MPI (0.35) | LMNAL3MBTL1MPITDP1BTN3A1 | |
| SCHEMBL30679810 | 0.91 | MPI (0.33) | LMNAL3MBTL1MPITDP1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113403358-A | Synthesis method and application of ALG1-CDG and PMM2-CDG biomarkers | 江南大学 | 2021-09-17 | — | — | CN | claimed |
| EP-1465616-B1 | TREATMENT OF STATIN SIDE EFFECTS USING URIDINE DERIVATIVES | MAGRAL LTD (AU) | 2010-06-30 | — | — | EP | claimed |
| EP-1054062-B1 | GLYCOSYLTRANSFERASE AND DNA ENCODING THE SAME | KYOWA HAKKO BIO CO LTD (JP) | 2009-06-03 | — | — | EP | claimed |
| EP-0886639-B1 | SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES | GLYCOMIMETICS INC (US) | 2008-05-28 | — | — | EP | claimed |
| US-7238100-B2 | β1,3-galactosyltransferase and DNA encoding the same | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-03 | — | — | US | claimed |
| EP-0481038-B1 | SACCHARIDE COMPOSITIONS, METHODS AND APPARATUS FOR THEIR SYNTHESIS | UNIV PENNSYLVANIA (US) | 2002-10-02 | — | — | EP | claimed |
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | OREGON STATE UNIVERSITY (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250361477-A1 | PRODUCTION OF AN OLIGOSACCHARIDE MIXTURE BY A CELL | INBIOSE NV (BE) | 2025-11-27 | — | — | US | disclosed |
| US-20250243525-A1 | BIOCATALYTIC MANUFACTURE OF SUGAR NUCLEOTIDES | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250188504-A1 | PRODUCTION OF A MIXTURE OF MAMMALIAN MILK OLIGOSACCHARIDES BY A CELL | INBIOSE N.V. (BE) | 2025-06-12 | — | — | US | disclosed |
| CN-119768515-A | Biocatalytic manufacture of sugar nucleotides | 齐姆特罗尼克斯催化系统股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-119677538-A | Cancer immunotherapy for promotion of hyperacute rejection | 康奈尔大学 | 2025-03-21 | — | — | CN | disclosed |
| CN-119235684-A | Dermatological anti-wrinkle composition, preparation method and application thereof | 优然创新(北京)技术研发中心有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2006091515-A2 | TUMOUR VACCINES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091515-A2 | TUMOUR VACCINES | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1509234-A1 | TREATMENT OF MUCOSITIS | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003099297-A1 | TREATMENT OF MUCOSITIS | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030167536-A1 | Plant adpglucose pyroghophatase, method for the production thereof, its use in the production of assay devices and for obtaining transgenic plants | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2003-09-04 | — | — | US | disclosed |
| EP-1253198-A1 | PLANT ADPGLUCOSE PYROPHOSPHATASE, METHOD FOR THE PRODUCTION THEREOF, ITS USE IN THE PRODUCTION OF ASSAY DEVICES AND FOR OBTAINING TRANSGENIC PLANTS | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2002-10-30 | — | — | EP | disclosed |
| US-5109126-A | Labels for detecting and monitoring enzymes | WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY (US) | 1992-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534439-B2 | Xanthohumol derivatives and methods for making and using | MT-CO1, MT-CO2, PC | LMNA 3109/4885L3MBTL1 1057/4885MPI 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.